FluoGuide (FLUO.ST) Stock Analysis & AI Equity Report
FluoGuide (FLUO.ST) overview
FluoGuide (FLUO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, FluoGuide reported revenue of DKK 0m and operating profit of DKK -41.0m; the year-end share price was 34.30 SEK and market capitalisation was SEK 482m. FluoGuide is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get FluoGuide's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About FluoGuide
FluoGuide A/S is a clinical-stage biotechnology company developing FG001, a fluorescent guidance product designed to highlight cancer during surgery and improve surgical precision. Its programs focus on oncology, with lead indications in glioblastoma and head and neck cancer. The company is also advancing clinical development and working with MedTech partners to support commercialization.
Generate the FluoGuide report
FluoGuide is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for FluoGuide and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.